Plotnick L P, Van Meter Q L, Kowarski A A
Pediatrics. 1983 Mar;71(3):324-7.
Children with growth failure, normal growth hormone responses to stimulation tests, and low somatomedin levels are being recognized with increasing frequency. Sixteen patients, aged 2 to 17 years, with these findings were studied. When treated with human growth hormone, the mean plasma somatomedin-C levels of these patients increased from 0.19 +/- 0.05 (SD) U/mL to 2.29 +/- 1.11 U/mL (P less than .001) and mean growth velocity increased from 3.6 +/- 1.6 (SD) cm/yr to 7.4 +/- 2.9 cm/yr at 8 months of treatment (P less than .001). The effect of human growth hormone therapy on the whole group was statistically significant, but the effect on individuals was highly variable. There was no correlation between magnitude of the increase in somatomedin-C and growth response (r = .26, NS). Thus, the long-term growth-promoting effect of human growth hormone therapy in this group of patients could not be predicted from the magnitude of the somatomedin-C responses.
生长发育迟缓、生长激素对刺激试验反应正常但生长介素水平较低的儿童正越来越频繁地被发现。对16名年龄在2至17岁、有这些表现的患者进行了研究。这些患者接受人生长激素治疗时，其血浆生长介素-C平均水平从0.19±0.05（标准差）U/mL增至2.29±1.11 U/mL（P<0.001），且治疗8个月时平均生长速度从3.6±1.6（标准差）cm/年增至7.4±2.9 cm/年（P<0.001）。人生长激素治疗对整个组的效果具有统计学意义，但对个体的效果差异很大。生长介素-C增加幅度与生长反应之间无相关性（r = 0.26，无显著性差异）。因此，无法根据生长介素-C反应的幅度来预测人生长激素治疗对该组患者的长期促生长作用。
